Cited by 929Glioma Diagnosis and TreatmentPARP inhibition in cancer therapyCancer survivorship and care

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Open access

Yung, W K A, Albright, R E, Olson, J, Fredericks, R, Fink, K, Prados, M D, Brada, M, Spence, A, Hohl, R J, Shapiro, W, Glantz, M, Greenberg, H, Selker, R G, Vick, N A, Rampling, R, Friedman, H, Phillips, P, Bruner, J, Yue, N, Osoba, D, Zaknoen, S, Levin, V A·2000·British Journal of Cancer

DOI 10.1054/bjoc.2000.1316PMC PMC2363506

Open this paper in CoChat — free account Open PDF

Abstract

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1054/bjoc.2000.1316

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005 · cited 1×
“The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 [+3]) (Aaronson et al, 1993; Osoba et al, 1997) and the Brain Cancer Module 20 (BCM20) (Osoba et al, 1996) questionnaires were used to measure HRQL. Questionnaires were administered on day 1…”
MethodSelf-citation
Measurement of health status
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982 · cited 1×
“A 10-unit change on a 0–100 scale was deemed significant if it lasted for at least 8 weeks (Jaeschke et al, 1989; Juniper et al, 1994; King, 1996; Ware et al, 1998).”
Background
Untitled work
(1994) · Medical Entomology and Zoology · Cited by 4,156
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016 · cited 1×
“Meaning of changes in HRQL scores was addressed by the method of Osoba et al (1998).”
MethodSelf-citation
EORTC QLQ-C30 Scoring Manual
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824 · cited 1×
“A 10-unit change on a 0–100 scale was deemed significant if it lasted for at least 8 weeks (Jaeschke et al, 1989; Juniper et al, 1994; King, 1996; Ware et al, 1998).”
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30
King, M. T. (1996) · Quality of Life Research · doi:10.1007/bf00439229 · Cited by 666
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E. S., Blackledge, G. R. P., Slack, J., Rustin, G. J. S., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M. F. G., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488 · cited 3×
“TMZ has notable antitumour activity against recurrent GBM, recurrent anaplastic astrocytoma, and advanced malignant melanoma, and other refractory cancers (Newlands et al, 1992, 1996; O’Reilly et al, 1993; Bleehen et al, 1995; Bower et al, 1997).”
BackgroundResult
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, andmdr gene expression in colorectal cancer
Mayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K., & Ludwig, H. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8 · Cited by 407
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L. M., Stone, R., BAIG, G. U., Goddard, C. P., Gibson, N. W., & Slack, J. A. (1987) · PubMed · Cited by 387

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 601–700 of 928

Brain metastases of breast cancer
Melisko, M., Kunwar, S., Prados, M. D., Berger, M. S., & Park, J. W. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.2.253 · Cited by 14
Self-citation
Case Report: A Patient with Primary CNS Lymphoma Treated with Temozolomide to Complete Response
Lerro, K. A., & Lacy, J. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1019682400415 · Cited by 14
“It is approved in the United States for anaplastic astrocytoma and in Europe for glioblastoma multiforme [9,10].”
Background
Surgery, radiotherapy and temozolomide in treating high-grade gliomas
Parlato, C. (2006) · Frontiers in bioscience · doi:10.2741/1881 · Cited by 14
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Martín, M. G., Bruna, J., Clopes, Fort, Gil, & Martinez, M. (2009) · Cancer Management and Research · doi:10.2147/cmr.s5598 · Cited by 13
Phase Ii Trial of Temozolomide and Reirradiation Using Conformal 3D-Radiotherapy in Recurrent Brain Gliomas
Osman, M. A. M., & Mohamed, H. H. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu330.16 · Cited by 13
Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
Desjardins, A., Herndon, J. E., McSherry, F., Ravelo, A., Lipp, E., Healy, P. N., Peters, K. B., Sampson, J. H., Randazzo, D. M., Sommer, N., et al. (2019) · Health Science Reports · doi:10.1002/hsr2.114 · Cited by 13
“Aspartate aminotransferase increased 16 (22) 1 (1) 2 (3) 0 Gastrointestinal disorders Nausea 33 (45) 7 (9) 0 0 Diarrhea 26 (35) 3 (4) 2 (3) 0”
BackgroundInfluentialSelf-citation
Headache attributed to non-vascular intracranial disorder
Diener, H., Johansson, U., & Dodick, D. W. (2010) · Handbook of clinical neurology · doi:10.1016/s0072-9752(10)97050-4 · Cited by 13
The Role of Radiotherapy and Chemotherapy in the Treatment of Primary Adult High Grade Gliomas: Assessment of Patients for These Treatment Approaches and the Common Immediate Side Effects
Philip-Ephraim, E. E., Eyong, K. I., Williams, U. E., & Ephraim, R. P. (2012) · ISRN Oncology · doi:10.5402/2012/902178 · Cited by 13
“These studies have consistently demonstrated clear benefit creditable to TMZ as regards progression free survival, increase in quality of life, and increase in 2 year survival [36–38].”
Background
Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
Gwak, H., Yee, G. T., Park, C., Kim, J. W., Hong, Y.-K., Kang, S., Kim, J. H., Seol, H. J., Jung, T., Chang, J. H., et al. (2013) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2013.54.6.489 · Cited by 13
“One week on–one week off”: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center
Galldiks, N., Berhorn, T., Blau, T., Dunkl, V., Fink, G. R., & Schroeter, M. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1048-z · Cited by 13
Are we done with dose-intense temozolomide in recurrent glioblastoma?
van den Bent, M. J., & Taal, W. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou157 · Cited by 13
Role of Extracellular Vesicles in Glioma Progression: Deciphering Cellular Biological Processes to Clinical Applications
Rana, R., Joon, S., Chauhan, K., Rathi, V., Ganguly, N. K., Kumari, C., & Yadav, D. K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201207100139 · Cited by 13
A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas
Ruiz, J., Case, D., Enevold, G. L., Rosdhal, R., Tatter, S. B., Ellis, T. L., McQuellon, R. P., McMullen, K. P., Stieber, V. W., Shaw, E. G., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0698-y · Cited by 13
Chemotherapy for malignant glioma
Nicholas, M. K., Lukas, R. V., & Bangalore, S. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.6.s41 · Cited by 13
Update on the therapeutic approaches to brain tumors
Lallana, E. C., & Abrey, L. E. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.5.655 · Cited by 13
Complications of chemotherapy in neuro-oncology
Marosi, C. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53502-3.00029-x · Cited by 13
“O N C O L O G Y 877 Table 57.3 Side-effects of temozolomide in different regimens Stupp et al., 2005 Yung et al., 2000 Wick et al., 2007 Brandes et al., 2006b Perry et al., 2008* Kong et al., 2006 Strick, pers. comm RT TMZ þ RT þ conc TMZ adj TMZ conc þ adj TMZ 5/28 TMZ 7/14 TMZ 21/28 TMZ 28/28 TMZ…”
BackgroundInfluential
Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma
Sarıca, F. B., Çekinmez, M., Tufan, K., Şen, O., Onal, H., Mertsoylu, H., Topkan, E., Pehlivan, B., Erdogan, B., & Altınörs, M. N. (2012) · Asian Journal of Neurosurgery · doi:10.4103/1793-5482.106650 · Cited by 12
Chemotherapy with cytotoxic and cytostatic agents in brain cancer
Blakeley, J. O., & Grossman, S. A. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52138-5.00017-7 · Cited by 12
Research Objectives, Statistical Analyses and Interpretation of Health-Related Quality of Life Data in Glioma Research: A Systematic Review
Coomans, M. B., Peeters, M. C. M., Koekkoek, J. A. F., Schoones, J. W., Reijneveld, J. C., TAPHOORN, M. J. B., & Dirven, L. (2020) · Cancers · doi:10.3390/cancers12123502 · Cited by 12
Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma
Lee, I., Yang, J., Huang, C. Y., Huang, H., Wu, Y., & Chen, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12704 · Cited by 12
“Temozolomide (TMZ), an oral alkylating agent, is the first‐line chemotherapy drug for GBM, as it can cross the blood‐brain barrier (3).”
Background
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas
Blakeley, J. O., Grossman, S. A., Mikkelsen, T., Rosenfeld, M. R., Peereboom, D. M., Nabors, B., Chi, A. S., Emmons, G., Ribas, I. G., Supko, J. G., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1876-0 · Cited by 12
Temozolomide in Newly Diagnosed Malignant Gliomas: Administered Concomitantly with Radiotherapy, and Thereafter as Consolidation Treatment
Yaman, E., Buyukberber, S., Üner, A., Çoşkun, U., Akmansu, M., Beneklı, M., Yamaç, D., Öztürk, B., Ali Osman, K. A. Y. A., z, R. Y. I. L. I., et al. (2008) · Onkologie · doi:10.1159/000127252 · Cited by 12
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide
Rosenthal, M. A., Ashley, D. L., & Cher, L. (2004) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2003.01.002 · Cited by 12
Phase I Study of Topotecan in Combination with Concurrent Radiotherapy in Adults with Glioblastoma
Lesimple, T., Hassel, M. B., Gedouin, D., Seigneuret, É., Carsin-Nicol, B., Hamlat, A., Riffaud, L., Simon, H., Malhaire, J. P., & Guégan, Y. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003647.66788.3b · Cited by 12
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05)
Grauer, O. M., Pascher, C., Hartmann, C. J., Zeman, F., Weller, M., Proescholdt, M. A., Brawanski, A. T., Pietsch, T., Wick, W., Bogdahn, U., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0548-y · Cited by 11
Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study
Johnston, A., Creighton, N., Parkinson, J., Koh, E.-S., Wheeler, H., Hovey, E. J., Rodriguez, M. J., & Currow, D. C. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz021 · Cited by 11
Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method
Liu, Y., Bao, Q., Chen, Z., Yao, L., Ci, Z., Wei, X., Wu, Y., Zhu, J., Sun, K., Zhou, G., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02803 · Cited by 11
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Garcia-Martin, M., Bruna, J., Clopes, A., Fort, Gil, & Martı́nez, M. E. (2009) · Cancer Management and Research · doi:10.2147/cmar.s5598 · Cited by 11
The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials
Li, Y., Hou, M., Lu, G., Ciccone, N., Wang, X., & Zhang, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168264 · Cited by 11
Malignant Gliomas in Adults
Norden, A. D., Drappatz, J., & Wen, P. Y. (2010) · Blue books of neurology · doi:10.1016/b978-0-7506-7516-1.00005-0 · Cited by 12
Treatment of Leptomeningeal Relapse of Medulloblastoma With Temozolomide
Hongeng, S., Visudtibhan, A., Dhanachai, M., Laothamatus, J., & Chiamchanya, S. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200210000-00024 · Cited by 11
Thirty years of progress in the management of low-grade gliomas
van den Bent, M. J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.03.001 · Cited by 9
Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians
Soffietti, R., Bertero, L., Pinessi, L., & Rudà, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0215-x · Cited by 10
“5 months longer than in the procarbazine arm [42].”
Background
Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases
Zhu, Y. J., Fu, L., Wang, J., Guo, D. L., Kong, L., & Yu, J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12795 · Cited by 10
Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics
Ruff, M. W., & Uhm, J. H. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0579-0 · Cited by 11
Z-scan method to measure the nonlinear optical behavior of cells for evaluating the cytotoxic effects of chemotherapy and hyperthermia treatments
Minaei, S. E., Ghader, A., Ardakani, A. A., Khoei, S., Asgari, H., & Ara, M. H. M. (2020) · Lasers in Medical Science · doi:10.1007/s10103-020-03148-2 · Cited by 10
“TMZ is an alkylating chemotherapeutic agent and causes cell death by methylating O6 position of guanine in DNA [36].”
BackgroundInfluential
Should radiotherapy be standard therapy for brain tumors in the elderly? cons
Chinot, O. L. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.11.027 · Cited by 10
Cystemustine in recurrent high grade glioma
Durando, X., Thivat, É., Roche, H. H., Bay, J., Lemaire, J., Verrelle, P., Lentz, M.-A., Chazal, J., Curé, H., & Chollet, P. J. M. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9096-7 · Cited by 10
“9 months for astrocytomas and oligodendrogliomas [16,25].”
Changing boundaries in the treatment of malignant gliomas
Brandes, A. A., Basso, U., & Pasetto, L. M. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.3.357 · Cited by 10
Tumor-treating fields: time for demystification
Weller, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy220 · Cited by 10
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features
Zhang, W., Lin, Y., Chen, B., Song, S. W., & Jiang, T. (2009) · Child s Nervous System · doi:10.1007/s00381-009-0995-3 · Cited by 9
“However, no effective therapeutic strategies are available for recurrent GBM; temozolomide and nitrosoureas produce only modest benefits; thus, experimental approaches have been tested [3].”
Background
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)
Demırcı, U., Tufan, G., Aktaş, B., Balakan, O., Alacacıoğlu, A., Dane, F., Engin, H., Ma, K., Günaydın, Y., Özdemir, N., et al. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1390-8 · Cited by 9
“8 months of median overall survival (OS) (Wong et al. 1999; Yung et al. 2000; Xu et al. 2010).”
Influential
Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease
Tamaskar, I., Mekhail, T. M., Dreicer, R., Olencki, T. E., Roman, S., Elson, P. J., & Bukowski, R. M. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9153-0 · Cited by 9
Single-agent bevacizumab is an effective treatment in recurrent glioblastoma
Hacıbekiroğlu, İ., Kodaz, H., Erdoğan, B., Türkmen, E., Özçelik, M., Esenkaya, A., Saygi, H. M., Uzunoğlu, S., & Çiçin, İ. (2015) · Medical Oncology · doi:10.1007/s12032-014-0460-3 · Cited by 9
“The prognosis is poor, after recurrence the median overall survival (OS) has been reported between 3 and 9 months in various publications [4].”
Background
Should we reoperate for recurrent high-grade astrocytoma?
Xu, J., Fang, J. Q., Shen, Y., Zhang, J., Liu, W.-G., & Shen, H. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0585-6 · Cited by 9
HIGH GRADE GLIOMAS
Leonard, A., Wolff, J. E. A., Sengupta, R., Marassa, J., Piwnica-Worms, D., Rubin, J., Pollack, I., Jakacki, R. I., Butterfield, L. H., Okada, H., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos102 · Cited by 9
Self-citation
Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients
Joo, J., Chang, J. H., Kim, J. H., Hong, Y.-K., Kim, Y., & Kim, C. (2012) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2012.52.2.92 · Cited by 9
Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization
Corsini, E., Gelati, M., Calatozzolo, C., Alessandri, G., Frigerio, S., Francesco, M. A. D., Poiesi, C., Parati, E. A., Croci, D., Boiardi, A., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0529-5 · Cited by 9
“high-grade glioma recurrence is the rule [26], and a reduction of intratumoral vessels could contribute to controlling minimal residual disease [21].”
Background
Multidrug delivery system based on polysaccharide nanocomplexes for controlled delivery of a combination of chemotherapeutics
Martino, A. D., Özaltın, K., Trusova, M. E., Постников, П. С., & Sedlařík, V. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.01.003 · Cited by 9
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
Roth, P., Hottinger, A. F., Hundsberger, T., Laubli, H. P., Schucht, P., Reinert, M., Mamot, C., Roelcke, U., Pesce, G. A., Höfer, S., et al. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20256 · Cited by 11
Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials
Chen, W., Liu, D., Liu, P., Kong, Z., Wang, Y., Wang, Y., & Ma, W. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.12 · Cited by 9
“The effect of carboplatin was not improved with RMP-7, a substance that elevates BBB permeability (9).”
Background
Quality-of-Life Assessment in Neurosurgical Patients
Bampoe, J., Siomin, V. E., & Bernstein, M. (2002) · Neurosurgery Quarterly · doi:10.1097/00013414-200206000-00006 · Cited by 9
“(different version based on SIP and Rand Corporation) Functional Living Index-Cancer (FLIC) Yung et al.(126) Giovagnoli et al.”
Background
Primary Tumors of the Central and Peripheral Nervous System
Weller, M., & Thomas, D. G. T. (2003) · Neurological Disorders · doi:10.1016/b978-012125831-3/50257-4 · Cited by 9
Temozolomide and MGMT forever?
Weller, M. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq016 · Cited by 9
Immune checkpoint blockade in glioblastoma: overcoming barriers through mechanism-informed, biomarker-guided, and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials
Mukherjee, A. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000120 · Cited by 8
Ten-year review of survival and management of malignant glioma in Hong Kong
Chan, D. T., Hsieh, S. Y., Lau, C. K. Y., Kam, M. K. M., Loong, H. H.-F., Tsang, W., Poon, D. M. C., & Poon, W. (2016) · Hong Kong Medical Journal · doi:10.12809/hkmj164879 · Cited by 8
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs
Bashiri, H., Moazzam‐Jazi, M., Karimzadeh, M. R., Jafarinejad‐Farsangi, S., Moslemizadeh, A., Lotfian, M., Karam, Z. M., Kheirandish, R., & Farazi, M. M. (2023) · Immunotherapy · doi:10.2217/imt-2022-0212 · Cited by 8
Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis
Kuhnhenn, J., Kowalski, T. E., Steenken, S., Ostermann, K., & Schlegel, U. S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0913-5 · Cited by 8
“With regard to salvage medical treatment, temozolomide and dose-intensified temozolomide [6–11], procarbazine [11], nitrosoureas [12–19], other cytostatic drugs [20, 21], procarbazine and nitrosourea-based combination therapy [22–25], and other combinations [26–34] have been evaluated in non-randomized trials [6–9, 12…”
Background
Neurocognitive functioning and quality of life in patients with recurrent malignant gliomas treated on a phase Ib trial evaluating topotecan by convection-enhanced delivery
Oberg, J. A., Dave, A., Bruce, J. N., & Sands, S. A. (2014) · Neuro-Oncology Practice · doi:10.1093/nop/npu014 · Cited by 8
Evaluation of cognitive functions and quality of life
TAPHOORN, M. J. B., & Klein, M. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52138-5.00014-1 · Cited by 8
A Common Sense Approach to Radiotherapy Planning of Glioblastoma Multiforme Situated in The Temporal Lobe
Bokstein, F., Kovner, F., Blumenthal, D. T., Ram, Z., Templehoff, H., Kanner, A. A., & Corn, B. W. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.01.053 · Cited by 8
Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma
Lee, A., Malakhov, N., Sheth, N., Wang, A., Han, P., & Schreiber, D. P. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.05.014 · Cited by 8
Prediction of the anti-glioma therapeutic effects of temozolomide through in vivo molecular imaging of MMP expression
Li, L., Du, Y., Xiang, D., Chen, L., Shi, Z., Tian, J., & Chen, X. (2018) · Biomedical Optics Express · doi:10.1364/boe.9.003193 · Cited by 8
Spinal Drop Metastasis of Glioblastoma–Two Case Reports, Clinicopathologic Features, Current Modalities of Evaluation, and Treatment with a Review of the Literature
Pande, A., Rajaraman, N., Sadiya, N., Patil, S., Pandian, S., Adhithyan, R., Rajendran, B., Jalali, R., & Ghosh, S. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.10.023 · Cited by 8
Gliomas Biology: Angiogenesis and Invasion
Caffo, M., Barresi, V., Caruso, G., La, G., Angela, M., Raudino, G., Alafaci, C., & Tomasello, F. F. (2013) · InTech eBooks · doi:10.5772/53487 · Cited by 8
Survival of Patients with Recurrent???Malignant Glioma Treated???with Temozolomide
Trippoli, S., Pelagotti, F., Messori, A., Vacca, F., Vaiani, M., & Maltoni, S. (2003) · Drugs in R&D · doi:10.2165/00126839-200304050-00002 · Cited by 8
Advances in the treatment of primary brain tumors: Dawn of a new era?
Gilbert, M. R. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0008-6 · Cited by 8
Chemotherapy of High-Grade Astrocytomas
Newton, H. B. (2006) · Elsevier eBooks · doi:10.1016/b978-012088410-0/50062-7 · Cited by 8
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Neyns, B., Sadones, J., Chaskis, C., Ridder, M. D., Keyaerts, M., Veld, P. I. '., & Michotte, A. (2005) · PubMed · Cited by 8
The effects of tibolone on the human primary glioblastoma multiforme cell culture and the rat C6 glioma model
Altinoz, M. A., Albayrak, S. B., Karasu, A., Sabancı, P. A., İmer, M., & Bılır, A. (2009) · Neurological Research · doi:10.1179/174313209x383268 · Cited by 8
The evolution of chemoradiation for glioblastoma: A modern success story
Mirimanoff, R. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0009-5 · Cited by 8
Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors
Terasaki, M., Bouffet, É., Katsuki, H., Fukushima, S., & Shigemori, M. (2007) · Surgical Neurology · doi:10.1016/j.surneu.2007.07.066 · Cited by 8
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
van den Bent, M. J., Chinot, O. L., & Cairncross, J. G. (2003) · Neuro-Oncology · doi:10.1215/s1522851702000285 · Cited by 8
NICE verdict on Temozolomide: where next?
Brada, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600134 · Cited by 8
“Two studies had no comparative group and one randomized Phase II study demonstrated small progression free survival gain compared to single agent Procarbazine with no survival benefit (Yung et al, 2000).”
BackgroundMethodSelf-citation
2001 Highlights From: 37th Annual American Society of Clinical Oncology Meeting San Francisco, CA May 12–15, 2001
Gibson, A. D., & Maung, K. (2001) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70745-8 · Cited by 8
Next Generation of Brain Cancer Nanomedicines to Overcome the Blood–Brain Barrier (BBB): Insights on Transcytosis, Perivascular Tumor Growth, and BBB Models
Bor, G., & Hosta‐Rigau, L. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300161 · Cited by 9
Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study
Dirven, L., Machingura, A., van den Bent, M. J., Coens, C., Bottomley, A., Brandes, A. A., Dômont, J., Idbaïh, A., Koekkoek, J. A. F., Reijneveld, J. C., et al. (2024) · Neuro-Oncology Practice · doi:10.1093/nop/npae091 · Cited by 7
“Previous studies in glioma patients 27–29 have shown that HRQoL deterioration is mainly driven by tumor growth, 30 and not treatment.”
Synthesis, characterization of novel isoindolinyl- and bis-isoindolinylphenylboronic anhydrides. Antiproliferative activity on glioblastoma cells and microglial cells assays of boron and isoindolines compounds
Mancilla, T., Ramírez, J. E. G., Jiménez, E. M., & Trejo‐Muñoz, C. R. (2019) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2019.04.011 · Cited by 7
Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis
Xu, Y., Guan, H., Yu, K., Ji, N., & Zhao, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1191480 · Cited by 7
An economic model to assess the cost-benefit of BNCT
Kulvik, M., Hermans, R., Linnosmaa, I., & Shalowitz, J. I. (2015) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2015.08.021 · Cited by 7
“…2005 the glioblastoma treatments were at their peak, so we will use year 2005 as our reference point for costs. adjuvant temozololamide is the present established care with a more than doubling of 2-year survival rates compared to radiation only (Stupp et al., 2002, 2009, 2005; Yung et al., 2000).”
Background
Prospective Clinical Trials of Brain Tumor Therapy: The Critical Role of Neurosurgeons
Lang, F. F., & Asher, A. L. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000041878.93045.f5 · Cited by 7
“Indeed, there are many examples of prospective clinical trials that have influenced neuro-oncologists’ practices, including studies of adjuvant radiation therapy [2], temozolamide [3,4], and BCNU wafers [5,6].”
Background
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia
Mabasa, V. H., & Taylor, S. C. M. (2006) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155206069161 · Cited by 7
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study
García, C. R., Slone, S. A., Morgan, R. M., Gruber, L., Kumar, S. S., Lightner, D. D., & Villano, J. L. (2018) · Medical Oncology · doi:10.1007/s12032-018-1198-0 · Cited by 7
Temozolomide for recurrent or progressive high-grade malignant glioma: Results of an Austrian multicenter observational study
Hassler, M. R., Micksche, M., Stockhammer, G., Pichler, J., Payer, F., Abuja, B., Deinsberger, R., & Marosi, C. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0576-3 · Cited by 7
“Temozolomide is an imidazotetrazinone, structurally related to dacarbazine, and has broad preclinical anti-tumor activity, good oral bioavailability of almost 100% [12] and significant drug penetration into the brain.”
Background
Impact of molecular profiling on clinical trial design for glioblastoma
Chakravarti, A., Tyndall, E., Palanichamy, K., Mehta, M. P., Aldape, K., & Loeffler, J. S. (2007) · Current Oncology Reports · doi:10.1007/bf02951429 · Cited by 7
Future trends in the treatment of brain tumours
Brandes, A. A., Lacombe, D., & Vecht, C. J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00301-x · Cited by 7
“4% [10] to 23.”
Background
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses
Schettini, F., Pineda, E., Rocca, A., Buché, V., Donofrio, C. A., Mazariegos, M., Ferrari, B., Tancredi, R. J., Panni, S., Cominetti, M., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae338 · Cited by 6
Glioblastoma diagnostics and prognostic biomarkers: Current status in medicine and exosome derivation
Rana, R., Kumari, B., Kumari, J., & Ganguly, N. K. (2019) · Current Medicine Research and Practice · doi:10.1016/j.cmrp.2019.03.001 · Cited by 7
New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme
Zhang, M., Jia, Y., Li, P., Qiao, Y., & Han, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00559 · Cited by 6
Bevacizumab for Glioblastoma—A Promising Drug or Not?
Nagane, M., & Nishikawa, R. (2013) · Cancers · doi:10.3390/cancers5041456 · Cited by 6
“that was 18% [6].”
Evolution of care for patients with relapsed glioblastoma
Balañá, C., Villà, S., & Teixidor, P. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.152 · Cited by 6
A Retrospective Evaluation of Bevacizumab Treatment in Patients with Progressive Malignant Glioma in Northern Sweden
Sandström, M., Laudius, M., Lindqvist, T., Asklund, T., & Johansson, M. (2017) · Anticancer Research · doi:10.21873/anticanres.11524 · Cited by 6
Physical approaches to treat glioblastoma
Latifyan, S., Micheli, R. D., & Hottinger, A. F. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000689 · Cited by 6
The Added Value of Bevacizumab Concomitantly Administered with Carboplatin versus Carboplatin Alone in Patients with Recurrent Glioblastomas
Kaloshi, G., Djamandi, P., Cakani, B., Braçe, G., Rroji, A. J., & Petrela, M. (2015) · Tumori Journal · doi:10.5301/tj.5000210 · Cited by 6
Radiotherapy with temozolomide provides better survival in the newly diagnosed glioblastoma multiforme: A meta-analysis
An, Z., Wang, C., Zhu, N., & Wang, L. (2015) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.168184 · Cited by 6
The Effect of Sequential Radiochemotherapy in Preirradiated Malignant Gliomas in a Phase II Study
Schäfer, U., Micke, O., Schüller, P., Schuck, A., & Willich, N. A. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021898.31923.bd · Cited by 6
Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy
Blumenthal, D. T., & Schulman, S. F. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.5.683 · Cited by 6
Surgical Management of Recurrent Intracranial Gliomas
Ferguson, S. D., Momin, E. N., & Weinberg, J. S. (2017) · Progress in neurological surgery · doi:10.1159/000464438 · Cited by 6
Stereotactic radiosurgery for recurrent high-grade gliomas: a systematic review
Kite, T. S., Bossinger, B., Yadlapalli, V., Jaffee, S., Herbst, J., Karlovits, S., Wegner, R. E., & Shepard, M. J. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05156-0 · Cited by 5
“At one year of clinical follow slightly more than half months respectively [10–20 ].”
Maligne Gliome—Chemotherapie
Hau, P., & Bogdahn, U. (2004) · Der Onkologe · doi:10.1007/s00761-003-0648-1 · Cited by 5

Authors: Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R. G., Vick, N. A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., & Levin, V. A.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Emory University (US)
University of Mississippi Medical Center (US)
The University of Texas Southwestern Medical Center (US)
University of California, San Francisco (US)
Royal Marsden NHS Foundation Trust (GB)
University of Washington (US)
University of Iowa Hospitals and Clinics (US)
Barrow Neurological Institute (US)
Memorial Hospital of Rhode Island (US)
University of Michigan (US)
Western Pennsylvania Hospital (US)
Evanston Hospital (US)
Beatson West of Scotland Cancer Centre (GB)
Duke University (US)
BC Cancer Agency (CA)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
ORCID: Yung, W K A
Olson, J
Prados, M D
Glantz, M
Friedman, H
Levin, V A
Venue: British Journal of Cancer
Publisher: Springer Science and Business Media LLC
Published: 2000-09
Volume: 83
Issue: 5
Pages: 588-593
ISSN: 0007-0920 (ISSN-L)
1532-1827
DOI: 10.1054/bjoc.2000.1316
PMC: PMC2363506
OpenAlex: W1977392502
Cited by: 929
References: 27
Citations by year: 2026: 7 · 2025: 9 · 2024: 8 · 2023: 23 · 2022: 19 · 2021: 21 · 2020: 21 · 2019: 20 · 2018: 27 · 2017: 23 · 2016: 31 · 2015: 32 · 2014: 33 · 2013: 38 · 2012: 50
FWCI: 21.15
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
Locations: British Journal of Cancer (publishedVersion, cc-by-nc-sa)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords: temozolomide, procarbazine, glioblastoma, first relapse, progression-free survival, overall survival, health-related quality of life, alkylating agents, oral chemotherapy, treatment safety
MeSH terms: Temozolomide, Adult, Aged, Antineoplastic Agents, Brain Neoplasms, Dacarbazine, Female, Glioblastoma, Humans, Male, Middle Aged, Procarbazine, Prognosis, Quality of Life, Recurrence, Time Factors, Gliosarcoma, Disease-Free Survival, Antineoplastic Agents, Alkylating

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks